FDA Can Now Regulate Ozempic Compounders After Novo Nordisk Court Challenge

A recent court ruling has cleared the way for the Food and Drug Administration (FDA) to potentially take action against companies that compound versions of the drug Ozempic. This development follows a legal challenge involving Novo Nordisk, the manufacturer of Ozempic. The court’s decision removes a legal obstacle that previously limited the FDA’s ability to regulate compounders producing versions of Ozempic. Compounding pharmacies create customized medications, often when a drug is in short supply or a patient has specific needs. Novo Nordisk initiated legal action related to the compounding of its drug. With this ruling, the FDA now possesses greater authority to oversee and potentially restrict the activities of these compounding pharmacies related to Ozempic.

Newsflash | Powered by GeneOnline AI
Date: April 25, 2025

Author

Mark Chiang